SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback